Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 19, 2021Received FDA IDE Approval for Pivotal Study of C-Scan®
- Mar 15, 2021Company expects to commence U.S. pivotal trial in late 2021
- Aug 6, 2020IDE submission to the FDA for C-Scan® planned for the end of 2020; Initiation of a U.S. pivotal study planned for 2021
- May 27, 2020Strengthened balance sheet through a total of $16.3 million in registered direct offerings and a private placement of ordinary shares in the first half of 2020
-
Mar 6, 2020Company planning to initiate a U.S. pivotal study of the C-Scan System in late 2020
-
Dec 30, 2019Advancing towards IDE submission to the FDA, targeting initiation of U.S. pivotal study in late 2020
-
Dec 20, 2019
-
Nov 6, 2019Successfully launched U.S. pilot study and reported positive final results from post-CE approval study of the C-Scan® System
-
Aug 19, 2019GE Healthcare facility in Chicago to support clinical investigation needs of the C-Scan® System in the U.S.